PSM-101 / PrecisemAb - LARVOL DELTA

Integrative design of PSM101 Lock-antibody for EGFR-positive tumors through clinical protease profiling and structure-based computer simulation (AACR 2026) - "Objective: On-target toxicity remains a major limitation of anti-EGFR antibodies, as exemplified by a 9.8% discontinuation rate in cetuximab-treated patients due to skin toxicity. We developed a protease-activated EGFR Lock-antibody, PSM101, with markedly improved tumor selectivity and strong therapeutic efficacy. MSCS 2.0 provides a predictive framework for early-stage optimization of pro-antibodies, which may accelerate next-generation antibody drug development and reduce clinical toxicity. Ongoing studies include safety evaluation of PSM101 in cynomolgus monkeys."

Clinical • Gastric Cancer • Head and Neck Cancer • Oncology • Solid Tumor • EGFR